GRIFFITH UNIVERSITY

FDA Grants Fast Track Designation to Sanofi's mRNA Chlamydia Vaccine Candidate

2 months ago

• The US FDA has granted fast track designation to Sanofi's mRNA vaccine candidate for chlamydia prevention, recognizing its potential to address a serious unmet public health need. • The vaccine aims to protect against primary genital tract infection and reinfection by Chlamydia trachomatis, with a Phase 1/2 clinical trial in adults aged 18-29 set to begin imminently. • With 129 million global chlamydia cases reported in 2020 and over 80% being asymptomatic, the vaccine could transform prevention efforts where current antibiotic treatments have failed to control rising infection rates.

First Clinical Trial of Olfactory Nerve 'Bridges' for Spinal Cord Injury Treatment Begins

7 months ago

• A Phase I clinical trial has commenced to evaluate the safety and efficacy of transplanting olfactory ensheathing cell nerve bridges for chronic spinal cord injury. • The trial utilizes nerve bridges made from the patient's own purified nasal cells, combined with intensive rehabilitation, to encourage nerve regeneration at the injury site. • This approach addresses technical limitations of previous cell transplantation trials by using innovative nerve bridges and high-purity olfactory cells. • The study seeks volunteers with chronic spinal cord injuries and is funded by various organizations, including the Medical Research Future Fund and the Perry Cross Spinal Research Foundation.

Clinical Trials Market to Reach $85.37 Billion by 2033, Driven by Globalization and Precision Medicine

7 months ago

• The clinical trials market is projected to reach USD 85.37 billion by 2033, driven by the increasing globalization of clinical trials and the need to access diverse patient populations. • The expansion of precision medicine is creating significant opportunities for clinical trials focused on validating targeted therapies and identifying relevant biomarkers. • North America currently dominates the clinical trials market due to its robust healthcare infrastructure and favorable regulatory environment, with Europe showing strong growth. • Recent developments include FDA approval of Spinogenix's ALS trial and the NHS launch of a platform to accelerate personalized cancer vaccine clinical trials.

Intranasal COVID-19 Vaccine CDO-7N-1 Advances to Clinical Trials

9 months ago

• A novel intranasal COVID-19 vaccine, CDO-7N-1, developed by Griffith University and licensed to Indian Immunologicals, is ready for clinical trials. • CDO-7N-1 induces robust mucosal and systemic immunity against all major SARS-CoV-2 proteins, offering broad protection against current and emerging variants. • Preclinical studies demonstrate that the single-dose, live-attenuated vaccine provides cross-protection, prevents transmission and reinfection, and reduces variant generation. • The vaccine exhibits stability at 4°C for seven months, making it suitable for widespread distribution, especially in low- and middle-income countries.